Amedeo Smart

Free Medical Literature Service




  Free Subscription

Articles published in
    September 2021
  1. CERVANTES F, Ross DM, Radinoff A, Palandri F, et al
    Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study.
    Leukemia. 2021 Sep 2. pii: 10.1038/s41375-021-01396.
    >> Share

    August 2021
  2. FEURSTEIN S, Churpek JE, Walsh T, Keel S, et al
    Germline variants drive myelodysplastic syndrome in young adults.
    Leukemia. 2021;35:2439-2444.
    >> Share

  3. GURNARI C, Pagliuca S, Patel BJ, Awada H, et al
    Implication of PIGA genotype on erythrocytes phenotype in Paroxysmal Nocturnal Hemoglobinuria.
    Leukemia. 2021;35:2431-2434.
    >> Share

    June 2021
  4. GURNARI C, Durrani J, Pagliuca S, Kishtagari A, et al
    Novel invariant features of Good syndrome.
    Leukemia. 2021;35:1792-1796.
    >> Share

    May 2021
  5. CERVANTES F, Ross DM, Radinoff A, Palandri F, et al
    Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study.
    Leukemia. 2021 May 20. pii: 10.1038/s41375-021-01261.
    >> Share

    April 2021
  6. YOROIDAKA T, Hosokawa K, Imi T, Mizumaki H, et al
    Hematopoietic stem progenitor cells lacking HLA differ from those lacking GPI-anchored proteins in the hierarchical stage and sensitivity to immune attack in patients with acquired aplastic anemia.
    Leukemia. 2021 Apr 6. pii: 10.1038/s41375-021-01202.
    >> Share

  7. ZHANG L, Chen JY, Kerr C, Cobb BA, et al
    Reduced red blood cell surface level of Factor H as a mechanism underlying paroxysmal nocturnal hemoglobinuria.
    Leukemia. 2021;35:1176-1187.
    >> Share

    March 2021
  8. LUNDGREN S, Keranen MAI, Kankainen M, Huuhtanen J, et al
    Somatic mutations in lymphocytes in patients with immune-mediated aplastic anemia.
    Leukemia. 2021 Mar 30. pii: 10.1038/s41375-021-01231.
    >> Share

  9. SEYFRIED AN, McCabe A, Smith JNP, Calvi LM, et al
    CCR5 maintains macrophages in the bone marrow and drives hematopoietic failure in a mouse model of severe aplastic anemia.
    Leukemia. 2021 Mar 20. pii: 10.1038/s41375-021-01219.
    >> Share

  10. FATTIZZO B, Ireland R, Dunlop A, Yallop D, et al
    Clinical and prognostic significance of small paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndrome and aplastic anemia.
    Leukemia. 2021 Mar 4. pii: 10.1038/s41375-021-01190.
    >> Share

    November 2020
  11. SPORTOLETTI P, Sorcini D, Guzman AG, Reyes JM, et al
    Bcor deficiency perturbs erythro-megakaryopoiesis and cooperates with Dnmt3a loss in acute erythroid leukemia onset in mice.
    Leukemia. 2020 Nov 6. pii: 10.1038/s41375-020-01075.
    >> Share

    July 2020
  12. HOSOKAWA K, Yamazaki H, Tanabe M, Imi T, et al
    High-dose romiplostim accelerates hematologic recovery in patients with aplastic anemia refractory to eltrombopag.
    Leukemia. 2020 Jul 3. pii: 10.1038/s41375-020-0950.
    >> Share

    June 2020
  13. LIU L, Zhang Y, Jiao W, Zhou H, et al
    Comparison of efficacy and health-related quality of life of first-line haploidentical hematopoietic stem cell transplantation with unrelated cord blood infusion and first-line immunosuppressive therapy for acquired severe aplastic anemia.
    Leukemia. 2020 Jun 26. pii: 10.1038/s41375-020-0933.
    >> Share

    October 2019
  14. BONO E, McLornan D, Travaglino E, Gandhi S, et al
    Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome.
    Leukemia. 2019;33:2495-2505.
    >> Share

    August 2019
  15. AWADA H, Rahman S, Durrani J, Asad MF, et al
    Leukemia evolving from paroxysmal nocturnal hemoglobinuria.
    Leukemia. 2019 Aug 20. pii: 10.1038/s41375-019-0555.
    >> Share

    July 2019
  16. RIBEZZO F, Snoeren IAM, Ziegler S, Stoelben J, et al
    Rps14, Csnk1a1 and miRNA145/miRNA146a deficiency cooperate in the clinical phenotype and activation of the innate immune system in the 5q- syndrome.
    Leukemia. 2019;33:1759-1772.
    >> Share

    June 2019
  17. HOSOKAWA K, Mizumaki H, Elbadry MI, Saito C, et al
    Clonal hematopoiesis by SLIT1-mutated hematopoietic stem cells due to a breakdown of the autocrine loop involving Slit1 in acquired aplastic anemia.
    Leukemia. 2019 Jun 11. pii: 10.1038/s41375-019-0510.
    >> Share

    April 2018
  18. MEI Y, Zhao B, Basiorka AA, Yang J, et al
    Age-related inflammatory bone marrow microenvironment induces ineffective erythropoiesis mimicking del(5q) MDS.
    Leukemia. 2018;32:1023-1033.
    >> Share

    January 2018
  19. NICOLOSI M, Mudireddy M, Lasho TL, Hanson CA, et al
    Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients.
    Leukemia. 2018 Jan 30. pii: 10.1038/s41375-018-0028.
    >> Share

    September 2017
  20. SAKAMOTO KM, Narla A
    Perspective on Diamond-Blackfan anemia: lessons from a rare congenital bone marrow failure syndrome.
    Leukemia. 2017 Sep 8. pii: leu2017314. doi: 10.1038/leu.2017.
    >> Share

    August 2017
  21. ALBITAR A, Townsley D, Ma W, De Dios I, et al
    Prevalence of somatic mutations in patients with aplastic anemia using peripheral blood cfDNA As compared with BM.
    Leukemia. 2017 Aug 23. doi: 10.1038/leu.2017.
    >> Share

    June 2017
  22. PLATZBECKER U, Symeonidis A, Oliva EN, Goede JS, et al
    A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes.
    Leukemia. 2017 Jun 19. doi: 10.1038/leu.2017.
    >> Share

    March 2017
  23. ROSS DM
    Responses to pomalidomide and placebo in myelofibrosis-related anaemia.
    Leukemia. 2017;31:532-533.
    >> Share

    February 2017
  24. DU W, Amarachintha S, Wilson A, Pang Q, et al
    The immune receptor Trem1 cooperates with diminished DNA damage response to induce preleukemic stem cell expansion.
    Leukemia. 2017;31:423-433.
    >> Share

    January 2017
  25. HAJEK R, Masszi T, Petrucci MT, Palumbo A, et al
    A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS).
    Leukemia. 2017;31:107-114.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016